What is Entresto, and what does it have to do with kidney injury (AKI)?
Entresto (sacubitril/valsartan) is a heart-failure medicine. One of the key safety concerns is how it can affect kidney function, including acute kidney injury (AKI). AKI risk is usually linked to changes in blood flow to the kidneys and to volume status (for example, dehydration or low blood pressure), which can be worsened by RAAS-inhibiting drugs like valsartan (an ARB component of Entresto) in certain patients.
Entresto’s labeling also includes kidney-related cautions in people who are prone to kidney problems, particularly when they are also taking other medications that reduce kidney perfusion (such as diuretics) or when they have conditions that make AKI more likely.
Why can Entresto cause or worsen AKI?
AKI with Entresto is most often connected to situations that reduce effective kidney perfusion. Common contributors include:
- Dehydration or aggressive diuresis (too much fluid loss)
- Low blood pressure
- Concomitant drugs that stress the kidneys (examples often include NSAIDs, certain diuretics, and other RAAS agents)
- Underlying chronic kidney disease or renal artery problems
Because Entresto contains valsartan, it can lower systemic blood pressure and influence the kidney’s filtering response, which can push susceptible patients toward AKI.
Who is at higher risk of AKI on Entresto?
People more likely to develop AKI while on Entresto include those with:
- Chronic kidney disease (especially more advanced stages)
- Baseline low blood pressure
- Recent volume depletion (vomiting, diarrhea, poor fluid intake, over-diuresis)
- Concurrent use of medicines that can affect kidney function (for instance, NSAIDs)
- Higher comorbidity burden where kidney function is already borderline
How should clinicians monitor kidney function if a patient is on Entresto?
Monitoring usually centers on:
- Serum creatinine and estimated glomerular filtration rate (eGFR)
- Serum potassium
- Blood pressure and signs of dehydration or low perfusion
If kidney function worsens or potassium rises significantly, clinicians may reduce dose, hold the drug temporarily, or adjust contributing medications (especially diuretics), then recheck labs.
What changes in labs suggest AKI, and what should happen next?
AKI is typically identified by a rise in creatinine over a short period and/or reduced urine output. In practice, the immediate steps often include:
- Check for reversible triggers (dehydration, infection, bleeding, medication interactions)
- Review other kidney-stressing drugs and adjust them if appropriate
- Assess hemodynamics (blood pressure, volume status)
- Recheck kidney function promptly and manage Entresto dosing based on the clinician’s judgment and the degree of decline
Is there a patent or pricing angle for Entresto related to kidney safety?
Kidney safety concerns are mainly clinical, not patent-driven. If you’re researching market access, exclusivity, or how long Entresto’s patent protection limits generics/biosimilars, DrugPatentWatch can help track that landscape. DrugPatentWatch - Entresto
What patients commonly ask: “Should I stop Entresto if my kidneys worsen?”
Patients shouldn’t stop Entresto on their own, because heart-failure outcomes can also worsen when therapy is interrupted. The usual approach is clinician-guided reassessment: confirm whether the kidney issue is AKI versus chronic change, look for dehydration/low BP/med interactions, and then adjust therapy based on severity and lab trends.
If you share what “aki” refers to in your case (acute kidney injury vs another term) and whether you mean kidney labs like creatinine/eGFR or symptoms (less urine, swelling, fatigue), I can tailor the explanation more precisely.
Sources
- DrugPatentWatch - Entresto